Tissue peptides
GHK-Cu
- 50 mg
Custom strengths on request
Not FDA-approved. On FDA's 503A list (May 14, 2026): Category 1 for non-injectable routes only, under evaluation. Source, May 14, 2026
At a glance
These dosages are a helpful guide, not a prescription. Every clinician is expected to do their own due diligence before prescribing.
Typical
0.4% topical cream; no better than placebo (venous ulcer trial)
Human study
- Frequency
- Twice daily (facial cream, women aged 50 to 59)
- Route
- Topical (facial, eye, thigh cream)
- Course
- 12 weeks (facial and eye cream studies)
Topical data only; no injectable human trial was found. FDA flags compounded injectable GHK-Cu for immunogenicity risk (aggregation, impurities).
Get a quote
Custom strengths on request. Prices are quoted per clinic.